Upcoming event
40th Annual EAU Congress
Back

Tag: STAMPEDE

Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

EMUC18: STAMPEDE trial